Drug Profile
JNJ 42165279
Alternative Names: JNJ-42165279; JNJ-5279Latest Information Update: 20 Dec 2022
Price :
$50
*
At a glance
- Originator Janssen-Cilag
- Class Amides; Anxiolytics; Benzodioxoles; Piperazines; Pyridines; Small molecules
- Mechanism of Action Fatty acid amide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Anxiety disorders; Pervasive child development disorders
Most Recent Events
- 28 Oct 2022 Janssen Research & Development completes a phase II trial in Pervasive child development disorders (In adolescents, In adults) in USA (PO) (NCT03664232)
- 02 Mar 2021 JNJ 42165279 is still in phase II trials for Anxiety disorders (Treatment-experienced) in USA, Moldova, Russia, Spain, Ukraine, United Kingdom (PO)
- 02 Mar 2021 Phase-II development for Pervasive child development disorders is ongoing in USA (PO)